The Treatment of Severe Posttraumatic Arthritis of the Ankle Joint
- Prednisolone plus a disease modifying antirheumatic drug improved outcomes in early rheumatoid arthritis. Svensson, B. // Evidence Based Medicine;Jun2006, Vol. 11 Issue 3, p79
The article presents a study that examines whether the addition of low dose prednisolone to the first use of a disease modifying antirheumatic drug (DMARD) would improve outcomes in patients with early rheumatoid arthritis. In this study, 259 patients 18 to 80 years of age with early rheumatoid...
- Commentary. Schattner, Ami // Evidence Based Medicine;Jun2006, Vol. 11 Issue 3, p79
The article comments on the medical research entitled "Prednisolone Plus a Disease Modifying Antirheumatic Drug Improved Outcomes in Early Rheumatoid Arthritis." The author stresses that the study was not blinded or long term and quality of life was not assessed. She also emphasizes that the...
- Chapter 9: Tips on pain control. Hunder, Gene // Mayo Clinic Straight Talk on Arthritis;2006, p211
Chapter 9 of the book "Mayo Clinic Straight Talk on Arthritis" is presented. It discusses the specific techniques for managing pain arising from arthritis. It explains simple treatments for acute pain as well as professional treatments other than medications. It also suggests that the pain...
- SierraSil. Williams, Clement // Total Health;Jun/Jul2004, Vol. 26 Issue 3, p29
Features SierraSil, a mineral supplement that promotes joint mobility, flexibility and active lifestyles for people with arthritis. Definition of arthritis; Features of SierraSil; Disadvantages of conventional therapy.
- HLA B27 allele types in homogeneous groups of juvenile idiopathic arthritis patients in Latvia. Stanevicha, Valda; Eglite, Jelena; Zavadska, Dace; Sochnevs, Arturs; Lazareva, Arina; Guseinova, Dinara; Shantere, Ruta; Gardovska, Dace // Pediatric Rheumatology;2010, Vol. 8, p26
Juvenile idiopathic arthritis (JIA) is a heterogeneous condition and therapeutic strategies vary in different JIA types. The routinely accepted practice to start with Sulphasalazine (SS) as the first line treatment in patients with HLA B27 positive JIA proves to be ineffective in a large...
- Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Conaghan, Philip G.; Hensor, Elizabeth M. A.; Keenan, Anne-Maree; Morgan, Ann W.; Emery, Paul // Rheumatology;Oct2010, Vol. 49 Issue 10, p1894
Objectives. Current UK management of RA initially employs conventional DMARDs, with biological therapy reserved for DMARD-resistant RA patients with persistently high 28-joint disease activity score (DAS-28). The aim of this study was to examine the effect on patient-reported function of...
- Who Has Arthritis? Levs, Melanie Lasoff // Arthritis Today;Nov/Dec2001, Vol. 15 Issue 6, p12
Presents statistical data about people with arthritis in the United States between 1996 and 1998.
- What are your arthritis pet peeves? // Arthritis Today;Jan/Feb2003, Vol. 17 Issue 1, p12
Presents the opinion of people with arthritis when people say something about their disability. Shirley Jampolsy of New York City; Joan Tubbs of Charleston, West Virginia; Ken Barron of North Canton, Ohio.
- ANTI-TNF AND CARDIOVASCULAR DISEASE. // Bandolier;Mar2006, Vol. 13 Issue 3, p4
This article discusses findings of a study conducted in Sweden, which investigated the use of anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis. The study included patients with rheumatoid arthritis who were treated with anti-TNF agents from 1999 to 2001. Initially, those treated...